연구동향 분석

순환종양핵산 검사의 임상 적용

원동주 허진호 김홍경 신새암 이승태 2022년

논문상세정보
인용/피인용
' 순환종양핵산 검사의 임상 적용' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Cell-free nucleic acids
  • Circulating tumor DNA
  • Liquid biopsy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
45 0

0.0%

' 순환종양핵산 검사의 임상 적용' 의 참고문헌

  • ctDNA applications and integration in colorectal cancer : an NCI Colon and Rectal–Anal Task Forces whitepaper
    Dasari A [2020]
  • Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
    Ulz P [2016]
  • Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing
    Narayan A [2012]
  • Ultrasensitive circulating tumor DNA analysis enables precision medicine : experimental workflow considerations
    Andersson D [2021]
  • Transrenal nucleic acids : from proof of principle to clinical tests
  • Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors
  • The main sources of circulating cell-free DNA : Apoptosis, necrosis and active secretion
    Hu Z [2021]
  • The emerging role of cell-free DNA as a molecular marker for cancer management
  • The diagnosis and treatment of prostate cancer : A review
    Litwin MS [2017]
  • The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : An evidence based appraisal
  • Serial circulating tumor DNA(ctDNA)and recurrence risk in patients(pts)with resectable colorectal liver metastasis(CLM)
    Tie J [2016]
  • Searching for new biomarkers in ovarian cancer patients : Rationale and design of a retrospective study under the Mermaid III project
    Hentze JL [2017]
  • Recommendations for the use of next-generation sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group
    Mosele F [2020]
  • RECIST 1. 1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy
    Bogani G [2019]
  • Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas
    Taniguchi K [2011]
  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
    Abbosh C [2017]
  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway) : an updated report from a multicentre, open-label, phase 2a, multiple basket study
  • Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation
    Miyazawa H [2008]
  • Pan-cancer circulating tumor DNA detection in over 10, 000 Chinese patients
    Zhang Y [2021]
  • PD-1 Blockade in tumors with mismatch-repair deficiency
    Asaoka Y [2015]
  • PARP inhibitors : Clinical relevance, mechanisms of action and tumor resistance
    Rose M [2020]
  • Overview of the national cancer screening programme and the cancer screening status in Korea
    Kim Y [2011]
  • Olaparib for metastatic castration-resistant prostate cancer
    de Bono J [2020]
  • Nuclear acids in human blood plasma
    Mandel P [1948]
  • Non-invasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade
  • Natural history of ovarian cancer
    Vargas AN [2014]
  • Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer
    Azuara D [2012]
  • Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
    Filipska M [2021]
  • Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients
    Taly V [2013]
  • Molecular profiling of ctDNA in pancreatic cancer : Opportunities and challenges for clinical application
    Sivapalan L [2021]
  • Metastatic patterns of prostate cancer : an autopsy study of 1, 589 patients
    Bubendorf L [2000]
  • Measuring tumor mutational burden(TMB)in plasma from mCRPC patients using two commercial NGS assays
    Qiu P [2019]
  • Management of relapsed ovarian cancer : a review
  • Liquid biopsy, ctDNA diagnosis through NGS
    Lin C [2021]
  • Liquid biopsy in ovarian cancer using circulating tumor DNA and cells : Ready for prime time?
    Asante DB [2020]
  • Liquid biopsy in breast cancer : A focused review
    Tay TKY [2021]
  • Liquid biopsies come of age : towards implementation of circulating tumour DNA
    Wan JCM [2017]
  • Liquid Biopsy for Advanced NSCLC : A Consensus Statement From the International Association for the Study of Lung Cancer
    Rolfo C [2021]
  • Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease : predictive role of bone resorption and formation markers evaluated at baseline
    Berruti A [2000]
  • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
    Chopra N [2020]
  • High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing
    Tsui NB [2012]
  • High fragmentation characterizes tumour-derived circulating DNA
    Mouliere F [2011]
  • Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA
    Meddeb R [2019]
  • Free DNA in the serum of cancer patients and the effect of therapy
    Leon SA [1977]
  • Free DNA and carcinoembryonic antigen serum levels : an important combination for diagnosis of colorectal cancer
    Flamini E [2006]
  • Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy
    Kim Y [2021]
  • Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva : A qualitative study
    Yao W [2016]
  • Enhanced detection of circulating tumor DNA by fragment size analysis
    Mouliere F [2018]
  • Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer
    Kopetz S [2019]
  • Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer : A randomized clinical trial
    Venook AP [2017]
  • Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
    Weigelt B [2017]
  • Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
    Gale D [2018]
  • Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
    Lau E [2020]
  • Detection of circulating tumor DNA in early and late stage human malignancies
  • Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay
    Asano H [2006]
  • Detection and quantification of rare mutations with massively parallel sequencing
    Kinde I [2011]
  • Current status of circulating tumor DNA liquid biopsy in pancreatic cancer
    Grunvald MW [2020]
  • Crystal structure of the nucleosome core particle at 2.8 A resolution
    Luger K. [1997]
  • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
    Siravegna G [2015]
  • Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer
    Sefrioui D [2015]
  • Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing
    Shin Saeam [2022]
  • Circulating tumor DNA: Where are we now? A mini review of the literature
  • Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies
    Freidin MB [2015]
  • Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer
    Luo H [2020]
  • Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
  • Circulating tumor DNA in advanced solid tumors : Clinical relevance and future directions
    Cheng ML [2021]
  • Circulating tumor DNA as a liquid biopsy for cancer
    Heitzer E [2015]
  • Circulating nucleic acids(CNAs)and cancer —a survey
  • Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA
  • Circulating cell-free DNA : a novel biomarker for response to therapy in ovarian carcinoma
    Kamat AA [2006]
  • Circulating cell free DNA : Preanalytical considerations
  • Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
  • Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer
    Dang HX [2020]
  • Cell-free DNA : An overview of sample types and isolation procedures
  • Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
    Bobillo S [2021]
  • Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA : a proof-of-principle
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018
    홍세리 [2021]
  • Calibration-free NGS quantitation of mutations below 0. 01% VAF
    Dai P [2021]
  • CA125 and ovarian cancer : A comprehensive review
    Charkhchi P [2020]
  • Analysis of the prognostic significance of circulating tumor DNA in metastatic castrate resistant prostate cancer
    Shaya J [2021]
  • An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
    Newman AM [2014]
  • About the possible origin and mechanism of circulating DNA apoptosis and active DNA release
    Stroun M [2001]